The study was conducted at RIMS general Hospital Psychiatry OP and study evaluated comparative efficacy and safety Lurasidone in comparison to Olanzapine  in first episode schizophrenia diagnosed based on ICD-10.126 first episode schizophrenia patients participated in the study out which 60 patients were in olanzapine group and 66 patients Lurasidone group. PANSS and CGI-I were used assess and compare efficacy. Lurasidone was non inferior to olanzapine in decreasing PANSS score from baseline to end of study at 12^th week (95% CI: -8.9 to 4.5). Lurasidone and Olanzapine were equally effective in treating the first episode schizophrenia.

Conclusion: In our study after analysis Lurasidone was equally efficacious in treating first episode of schizophrenia.

Keywords:  Lurasidone, Olanzapine, first episode schizophrenia, response rates, PANSS, CGI-I.

1. Häfner H, an der Heiden W. Epidemiology of Schizophrenia. The Canadian Journal of Psychiatry. 1997;42:139–151. doi:1177/070674379704200204
2. Messias, Erick, Chuan-Yu Chen, and William W Eaton. “Epidemiology of Schizophrenia: Review of Findings and Myths.” The Psychiatric Clinics of North America 30, no. 3 (September 2007): 323–38. https://doi.org/10.1016/j.psc.2007.04.007.
3. Jablensky, A., N. Sartorius, G. Ernberg, M. Anker, A. Korten, J. E. Cooper, R. Day, and A. Bertelsen. “Schizophrenia: Manifestations, Incidence and Course in Different Cultures. A World Health Organization Ten-Country Study.” Psychological Medicine. Monograph Supplement 20 (1992): 1–97.
4. Kumar, Ajit, Soumitra S. Datta, Stephen D. Wright, Vivek A. Furtado, and Paul S. Russell. “Atypical Antipsychotics for Psychosis in Adolescents.” The Cochrane Database of Systematic Reviews, no. 10 (October 15, 2013): CD009582. https://doi.org/10.1002/14651858.CD009582.pub2.
5. Ishibashi, Tadashi, Tomoko Horisawa, Kumiko Tokuda, Takeo Ishiyama, Masaaki Ogasa, Rie Tagashira, Kenji Matsumoto, et al. “Pharmacological Profile of Lurasidone, a Novel Antipsychotic Agent with Potent 5-Hydroxytryptamine 7 (5-HT₇) and 5-HT_1A Receptor Activity.” Journal of Pharmacology and Experimental Therapeutics 334, no. 1 (July 1, 2010): 171. https://doi.org/10.1124/jpet.110.167346
6. Rummel-Kluge, Christine, Katja Komossa, Sandra Schwarz, Heike Hunger, Franziska Schmid, Werner Kissling, John M Davis, and Stefan Leucht. “Second-Generation Antipsychotic Drugs and Extrapyramidal Side Effects: A Systematic Review and Meta-Analysis of Head-to-Head Comparisons.” Schizophrenia Bulletin 38, no. 1 (January 2012): 167–77. https://doi.org/10.1093/schbul/sbq042.
7. Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Duggan L, Kissling W, Leucht S. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010 Mar 17;(3):CD006654. doi: 10.1002/14651858.CD006654.pub2. Review. PubMed PMID: 20238348; PubMed Central PMCID: PMC4169107.
8. Bell M, Milstein R, Beam-Goulet J, Lysaker P, Cicchetti D. (1992): The Positive and Negative Syndrome Scale and the Brief Psychiatric Rating Scale. Reliability, comparability, and predictive validity. J Nerv Ment Dis180: 723–728
9. National Institute of Mental Health. (1976a): Clinical Global Impression. In Guy W (ed), ECDEU Assessment Manual for Psychopharmacology Revised Edition. Rockville, MD, National Institute of Mental Health, pp 218–222
10. Simpson G, Angus JA. (1970): A rating scale for extrapyramidal side effects. Acta Psychiat Scand45(Suppl 212):11–19
11. Leucht, Stefan, John M. Kane, Werner Kissling, Johannes Hamann, Eva Etschel, and Rolf R. Engel. “What Does the PANSS Mean?” Schizophrenia Research 79, no. 2–3 (November 15, 2005): 231–38. https://doi.org/10.1016/j.schres.2005.04.008.
12. Beasley CM, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S, the Olanzapine HGAP Study Group. (1996a): Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology124: 159–167
13. Citrome L. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Int J Clin Pract. 2011 Feb;65(2):189-210. doi: 10.1111/j.1742-1241.2010.02587.x. Epub 2010 Dec 3. Review. PubMed PMID: 21129135.
14. Amico, K Rivet. “Percent Total Attrition: A Poor Metric for Study Rigor in Hosted Intervention Designs.” American Journal of Public Health 99, no. 9 (September 2009): 1567–75. https:// doi.org/10.2105/AJPH.2008.134767.
15. Nakamura, Mitsutaka, Masaaki Ogasa, John Guarino, Debra Phillips, Joseph Severs, Josephine Cucchiaro, and Antony Loebel. “Lurasidone in the Treatment of Acute Schizophrenia: A Double-Blind, Placebo-Controlled Trial.” The Journal of Clinical Psychiatry 70, no. 6 (June 2009): 829–36. https://doi.org/10.4088/JCP.08m04905.
16. Risbood, Vineeta, Jennifer R. Lee, Jennifer Roche-Desilets, and Matthew A. Fuller. “Lurasidone: An Atypical Antipsychotic for Schizophrenia.” The Annals of Pharmacotherapy 46, no. 7–8 (August 2012): 1033–46. https://doi.org/10.1345/aph.1M721.
17. Goldman, Robert, Antony Loebel, Josephine Cucchiaro, Ling Deng, and Robert L. Findling. “Efficacy and Safety of Lurasidone in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study.” Journal of Child and Adolescent Psychopharm-acology 27, no. 6 (August 2017): 516–25. https://doi.org/10.1089/cap.2016.0189.

Dr. Kandavalli Sridevi M.D (Pharmacology)

Mobile 73826226669, Email: This email address is being protected from spambots. You need JavaScript enabled to view it.